Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alnuctamab - EngMab

Next Previous
Drug Profile

Alnuctamab - EngMab

Alternative Names: ALNUC; BMS-986349; CC-93269; EM-901

Latest Information Update: 05 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EngMab
  • Developer Celgene Corporation; EngMab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Diffuse large B cell lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 18 Mar 2025 Celgene terminates phase I trial in Multiple myeloma (Second-line therapy or greater) in Japan, Italy, Sweden, Spain, Germany, USA due to change in business priorities (IV and SC) (NCT03486067)
  • 30 May 2024 Celgene terminates the phase III ALUMMINATE trial in Multiple myeloma in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey and UK (NCT06232707) (EudraCT2023-509472-42)
  • 27 Mar 2024 Updated pharmacokinetics data from a phase I trial in Multiple myeloma presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top